AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Allogene Therapeutics, Inc. Director's Dealing 2021

Sep 21, 2021

33378_dirs_2021-09-20_7c70f3b0-ec9c-499d-a55b-7fc87812fd9e.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-09-10

Reporting Person: PF Equity Holdings 2 B.V. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	22032040.0000	Direct

Footnotes

F1: Shares acquired from its parent entity, Pfizer Inc. for no cash consideration.